BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 1591381)

  • 1. The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma.
    Bataille R; Chappard D; Klein B
    Int J Clin Lab Res; 1992; 21(4):283-7. PubMed ID: 1591381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of bone lesions in multiple myeloma and lymphoma.
    Roodman GD
    Cancer; 1997 Oct; 80(8 Suppl):1557-63. PubMed ID: 9362422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the pathogenesis of osteolysis in multiple myeloma patients.
    Giuliani N; Colla S; Rizzoli V
    Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bone hyperresorption in multiple myeloma].
    Beaudreuil J; Orcel P
    Presse Med; 2000 Mar; 29(9):492-7. PubMed ID: 10745943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The multiple myeloma bone eco-system and its relation to oncogenesis.
    Bataille R
    Morphologie; 2015 Jun; 99(325):31-7. PubMed ID: 26005000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of bone lesions in multiple myeloma.
    Bataille R; Chappard D; Klein B
    Hematol Oncol Clin North Am; 1992 Apr; 6(2):285-95. PubMed ID: 1582975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of clodronate in multiple myeloma.
    Delmas PD
    Bone; 1991; 12 Suppl 1():S31-4. PubMed ID: 1835398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of bone destruction in multiple myeloma.
    Terpos E; Christoulas D; Gavriatopoulou M; Dimopoulos MA
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28940410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of osteoclast function.
    Suda T; Nakamura I; Jimi E; Takahashi N
    J Bone Miner Res; 1997 Jun; 12(6):869-79. PubMed ID: 9169344
    [No Abstract]   [Full Text] [Related]  

  • 10. Mechanisms of osteolytic bone destruction.
    Mundy GR
    Bone; 1991; 12 Suppl 1():S1-6. PubMed ID: 1954046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of myeloma bone disease.
    Roodman GD
    Leukemia; 2009 Mar; 23(3):435-41. PubMed ID: 19039321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology of multiple myeloma bone disease.
    Lentzsch S; Ehrlich LA; Roodman GD
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1035-49, viii. PubMed ID: 17996587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cytokine-mediated bone resorption].
    Nakamura M; Uehara S; Nakamura H; Udagawa N
    Clin Calcium; 2014 Jun; 24(6):837-44. PubMed ID: 24870834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.
    Menu E; De Leenheer E; De Raeve H; Coulton L; Imanishi T; Miyashita K; Van Valckenborgh E; Van Riet I; Van Camp B; Horuk R; Croucher P; Vanderkerken K
    Clin Exp Metastasis; 2006; 23(5-6):291-300. PubMed ID: 17086356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bone hyperresorption in neoplastic diseases. Foreword].
    Vinceneux P
    Presse Med; 2000 Mar; 29(9):485-6. PubMed ID: 10745941
    [No Abstract]   [Full Text] [Related]  

  • 16. Macrophage colony-stimulating factor and interleukin-6 release by periprosthetic cells stimulates osteoclast formation and bone resorption.
    Neale SD; Sabokbar A; Howie DW; Murray DW; Athanasou NA
    J Orthop Res; 1999 Sep; 17(5):686-94. PubMed ID: 10569477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of glucocorticoids on the biologic activities of myeloma cells: inhibition of interleukin-1 beta osteoclast activating factor-induced bone resorption.
    Ishikawa H; Tanaka H; Iwato K; Tanabe O; Asaoku H; Nobuyoshi M; Yamamoto I; Kawano M; Kuramoto A
    Blood; 1990 Feb; 75(3):715-20. PubMed ID: 2297574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.
    Bataille R; Chappard D; Marcelli C; Dessauw P; Baldet P; Sany J; Alexandre C
    J Clin Invest; 1991 Jul; 88(1):62-6. PubMed ID: 2056131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for the secretion of an osteoclast stimulating factor in myeloma.
    Mundy GR; Raisz LG; Cooper RA; Schechter GP; Salmon SE
    N Engl J Med; 1974 Nov; 291(20):1041-6. PubMed ID: 4413338
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.